aseanostatin p5 has been researched along with mocetinostat in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akagawa, H; Ishida-Okawara, A; Kawaguchi, K; Kimoto, Y; Masuda, K; Nilubol, N; Shibata, M; Takano, Y; Tokuda, K; Watanabe, K | 1 |
| Aono, S; Kitahara, T; Mori, K | 1 |
2 other study(ies) available for aseanostatin p5 and mocetinostat
| Article | Year |
|---|---|
Purification and characterization of aseanostatins: actinomycete-derived fatty acid inhibitors to myeloperoxidase release from human polymorphonuclear leukocytes.
Topics: Actinomycetales; Anti-Bacterial Agents; Fatty Acids; Humans; Neutrophils; Peroxidase; Superoxides | 1991 |
Synthesis of both the enantiomers of aseanostatin P5 (sarcinic acid), an inhibitor of myeloperoxidase release, and four diastereomers of aggreceride A, a platelet aggregation inhibitor.
Topics: Fatty Acids; Glycerides; Magnetic Resonance Spectroscopy; Mass Spectrometry; Peroxidase; Platelet Aggregation; Spectrophotometry, Infrared; Stereoisomerism; Structure-Activity Relationship | 1995 |